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Part A: Protocol 
Purpose of the study 
  The aim of this project is to study the clinical and pathological features of prostate 
cancer in men from different racial groups in the Western Cape in an attempt to 
define the characteristics of the disease locally. Specifically we wanted to compare 
black with coloured and white patients. 
Background 
  Prostate cancer is among the most common non-cutaneous cancer diagnosed in 
men worldwide, and the first or second commonest cause of male cancer deaths in 
many countries (1). This applies to South Africa as well, where it is second only to 
lung cancer in terms of mortality (2). 
  African American men have been shown to have a higher incidence of prostate 
cancer, higher stage at presentation, higher histological grade, a greater propensity 
to relapse after curative treatment, and a higher disease-specific mortality (3,4). 
Men with West-African ancestry from elsewhere, such as South America, the United 
Kingdom and the Caribbean, have a similarly high rate of prostate cancer (5). 
Delayed diagnosis accounts in part for the higher stage at presentation and possibly 
some of the increased mortality.  This delay in diagnosis has been attributed to 
healthcare access problems, reduced health-seeking behaviour, and often health-
provider prejudice. Many studies have attempted to correct for these factors, and 
have concluded that there is most likely a real difference in tumour biology 
between African American men and other American men, and this is most likely due 
to underlying genetic factors (4).    
  Epidemiological studies on South African populations have uniformly found 
prostate cancer to be more common in white than black South Africans (2,6). 
However, Heyns, et al found that the black patients being diagnosed with prostate 
cancer at Tygerberg Hospital between 1995 and 2005 had higher PSA values at 
presentation, that their tumours were significantly more locally advanced and that 
they had a higher histological grade (7).  The impression of the authors of that study 
was that prostate cancer was more common in black South Africans than in other 
population groups, possibly in a similar way to African American populations.  These 
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seemingly discordant findings suggest that prostate cancer in the South African 
black population might be underdiagnosed by a large extent. Prostate cancer 
incidence within a population is heavily influenced by screening practices. The 
average black male in South Africa might be less likely to be screened for prostate 
cancer, and thus be less likely to have a prostate biopsy than one of his white, 
coloured or Indian counterparts. This is illustrated by the finding that the biopsy-
proven incidence in black men in South Africa is less than a quarter that of white 
South African men, but the mortality rate is more than double (2).     
It has also been our overall impression that of the men being referred for prostate 
biopsy in our unit, the black patients seemed to have higher PSA values, larger 
prostates, be more symptomatic, and have a higher chance of having prostate 
cancer diagnosed.  We have therefore set out to analyse our biopsy database to 
determine if that is the case. 
Methodology 
Literature review 
Searches will be conducted using the following Medline MeSH (Medical Subject 
Headings) strings: 
 Prostatic neoplasms / ethnology 
 Prostatic neoplasms / epidemiology, ethnology AND South Africa 
 Prostatic neoplasms / epidemiology, ethnology, aetiology AND Africa south of 
the Sahara 
Similar searches will be done in Google Scholar. 
 
Where studies cover similar material, the more recent articles will be favoured.  
Study design 
  All prostate biopsies done in the Department of Urology at Groote Schuur since 
2008 have been entered prospectively into a database containing demographic 
information, clinical findings, PSA values, and ultrasound findings, among other 
details. 
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  This study will be a retrospective review of the prostate biopsy database, with the 
intention of comparing age, self-reported race, symptoms, serum PSA values, 
measured prostate volume, presence of cancer, and histological grade. 
  The database in question currently contains over 1000 patients.  
Characteristics of study population 
  The prostate biopsy database contains 1027 patients from the beginning of 2008 
to the end of June 2014.  
  These patients had all been referred to the Urology service via normal channels 
and had biopsies as part of their routine clinical care. No patient was at any time 
specifically recruited for this research project, nor did any have a biopsy solely for 
the purpose of research. 
  All patients on the database will be included in the study unless: 
 Identifying data, age, PSA, prostate volume or histology are not available. 
 Biopsies have been limited (ie. fewer than 12 cores) or inadequate (ie. not 
representing prostatic tissue) and those biopsies have been negative for 
malignancy. 
  It is recognised that limited biopsies that are positive might result in 
underestimation of the grade of cancer diagnosed because of the fewer cores 
taken. It is, however, felt that this is not enough of a concern to exclude those 
patients from the analysis.   
  Being a retrospective review of records, this population would not be considered 
vulnerable or at risk. 
  This research project will be conducted within the Division of Urology at Groote 
Schuur Hospital. 
Recruitment and Enrolment 
  The patients on the database represent biopsies done during routine clinical 
practice within the Division of Urology. Indications for biopsy are an elevated serum 
PSA level or a palpably abnormal prostate on digital rectal examination. At our 
institution we do not routinely offer screening to asymptomatic men, but will do so 
on patient request after good counselling on the matter.  
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Research Procedures and Data Collection Methods 
  Transrectal ultrasound-guided (TRUS) biopsy of the prostate is the worldwide 
standard investigation for the definitive diagnosis of prostate cancer(8). The 
guidelines of the European Association of Urology recommend that 10 to 12 cores 
be taken at biopsy (9).    
  Note again that these biopsies have already been done as part of standard care. 
The description of the routine procedure is described for completeness. 
  Prostate biopsy is performed in the office setting after informed consent and the 
administration of a dose of prophylactic antibiotic. The patient is positioned on the 
examination bed in the left lateral decubitus position with knees pulled towards the 
chest. A full tube of local anaesthetic jelly is inserted transrectally and a digital 
rectal examination (DRE) performed.  A trans-rectal ultrasound probe with a biopsy 
guide attached is introduced into the rectum. Submucosal local anaesthetic 
injection can be done, but it is not our practice, as the procedure is generally 
equally well-tolerated without it. Ultrasound examination of the prostate is then 
performed. This includes measurement of dimensions in three planes (with a 
calculated estimated volume) as well as the noting of any abnormalities such as 
capsular distortion, focal hypo- or hyper-echoic areas, calcification or increased 
vascularity.  A spring-loaded needle biopsy gun is used to take two cores of prostate 
tissue from each of six different areas of the prostate – the left and right bases, mid 
zones and apices. Any hypoechoic areas visualised on ultrasound are sampled with 
additional biopsies. The cores from each sextant, and any additional biopsies, are 
sent for histology separately to give information about extent and location of the 
tumour.   
 The most common complications of the procedures are infection and bleeding, 
resulting in hospitalization in around 1.9% and death in less than 0.1% of patients 
(10). 
 The prostate biopsies are performed by one of the trainees in the department of 
urology.     
 Data from each patient are entered onto a pro-forma data sheet at the time of 
biopsy (see Appendix A), and the histology results then subsequently added to the 
database once they become available. 
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 Information gathered at each biopsy includes the patient’s name, hospital number, 
date of birth, age, presenting symptoms, PSA, findings on DRE, ultrasound findings 
and prostate size measurement.  
 A deficiency of the database is that the race of the patients has not been recorded. 
To obtain this information we plan to look up the subjects’ self-declared ethnicity, 
as recorded by the hospital administration staff on the computerised hospital 
administration system. 
 Incomplete data could be retrieved from the patient folders as necessary. 
Data Analysis 
 Data will be analysed with the assistance of a statistician.  
 The overall characteristics of the sample will be analysed and compared. 
 Differences between all of the collected variables with respect to the patient’s race 
group will be determined and tested for statistical significance.  Any potential 
confounding factors will be looked for and excluded as far as possible. 
Ethics  
 The study will be conducted according to the ethical guidelines and principles of 
the international Declaration of Helsinki, South African Guidelines for Good Clinical 
Practice and the Medical Research Council (MRC) Ethical Guidelines for Research.  
 Approval for this study has been granted by the Faculty of Health Sciences Human 
Research Ethics Committee of the University of Cape Town, after prior approval 
from the Surgical Departmental Research Committee.  The reference number is 
099/2015.  
 The prostate biopsy database has ongoing approval for use in clinical research 
within our department, with the most recent updated approval valid until 30 August 
2017.  The reference number for that is R033/2014. 
Benefits 
 As this is a retrospective review, there is no direct benefit to the patients. However, 
the data obtained may allow us to improve our clinical management of patients 
with suspected prostate cancer. If groups at higher risk can be identified within the 
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South African population, then these patients may benefit from targeted screening 
programmes in future.   
Privacy and Confidentiality 
 Patient confidentiality will be protected by keeping the hard copies of the data 
sheets in the urology registrar room, to which access is controlled by a combination 
lock. The electronic data (ie. spreadsheet) will be kept on the computer in the same 
room, which is further protected by a login code. Identifying data is necessary in the 
database, as it is used to check the histology results and allow access to the 
patients’ files should incomplete data or outcome need to be determined, but will 
be de-identified prior to statistical analysis. 
Expected outcomes 
 Based on the well-established risks conferred by African ancestry on prostate 
cancer incidence and severity, as described above, we hypothesised that the black 
patients in our series might similarly have worse clinical characteristics.  We 
expected that the pre-test PSA levels would be higher, that the prostate volumes 
would be larger, that prostate cancer would be diagnosed more frequently, and 
that it might be of a higher histological grade.  We anticipate delayed presentation 
being a factor in the clinical picture of our black patients. This is because our black 
patients are socio-economically disadvantaged and very often seem to be residents 
of the Eastern Cape who come to Cape Town because of real or perceived 
inadequacies of their local healthcare infrastructure. Determining the response to 
treatment and the treatment outcome is beyond the scope of this study. 
Dissemination of results 
 The results of this study will be submitted as a mini-dissertation to the University of 
Cape Town and, if accepted, will then be part of the public domain and be available 
online from the university library.  The second part of the dissertation will be 
submitted to various academic journals for peer review and publication.  The study 
will also be presented at one or more academic urology meetings in the city of Cape 
Town, as well as at the South African Urological Association annual congress.  
MJ Dewar – Investigating racial differences in clinical and pathological features of prostate cancer in South African men 
University of Cape Town May 2016 13 
Lay summary 
 Prostate cancer is a common cancer among men worldwide, becoming more 
common as men get older. In most countries around the world prostate cancer is 
one of the five most common causes of death from cancer in men (11).  
 Many scientific studies have shown that men in Africa, particularly in West Africa, 
and men elsewhere who have West African ancestry, are at particularly high risk for 
prostate cancer.  Not only do they have a higher chance of getting prostate cancer, 
but they also get it at a younger age.  Some studies have also shown that men with 
African ancestry have a more aggressive type of prostate cancer, have a worse 
outcome after treatment, and are more likely to die of prostate cancer (12).     
Unfortunately, most of this information comes from areas outside of Africa, such as 
the United States of America, Brazil, the Caribbean and the United Kingdom (13–
16). Information coming from Africa is often sparse, and compounded by problems 
with recording and reporting of cases.  Even when the proven cases of prostate 
cancer are well recorded, the numbers are often thought to be very much 
underestimated because of generally poor access to healthcare (17).  This seems to 
be true of South Africa too, where the incidence reported for South African men is 
one fifth that of the rate in America, and the rate in black South Africans is one 
tenth that of the rates reported in African American men (2,18).  
  In this study, we aimed to investigate whether the black African men seen at a 
tertiary hospital in Cape Town did have a higher chance of being diagnosed with 
cancer, and whether the characteristics of their cancer were more severe.  We did 
this by retrospectively analysing the details of approximately 1000 patients who had 
undergone a biopsy of the prostate between 2008 and 2014.  More specifically, we 
looked at:  age; whether they presented with symptoms of prostate problems or 
were picked up on PSA screening; the prostate-specific antigen (PSA) level; the size 
of the prostate; whether or not cancer was diagnosed, and if so, the histological 
grade and clinical stage. We hope that this information will help us to better 
understand who might be at increased risk for prostate cancer in our community. 
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Part B: Literature review 
Introduction 
  Cancer of the prostate (CaP) is one of the most common cancers diagnosed in 
men. Worldwide it is the second most frequent non-cutaneous cancer occurring in 
men and it is the fifth commonest cause of death due to cancer (11). In 2012 there 
were an estimated 1.112 million new cases and 307 000 deaths due to prostate 
cancer worldwide(11). The population adjusted incidence of prostate cancer in the 
United States is 137.9 per 100,000 population.  Thus it is the commonest cancer 
diagnosed in US men. There were an estimated 220,800 new cases in 2015 (19). The 
number of prostate cancer deaths reported in the United States in 2015 was 
27,540, which made it the second commonest cause of death in males after lung 
cancer (19). In South Africa between 2006 and 2009, prostate cancer was the 
second leading cause of deaths due to cancer in men after lung cancer (2). 
  It has been well established that prostate cancer is more common in men of 
African descent (13–15), and there is some evidence that some African populations 
might share a similarly high incidence of prostate cancer (20). The exact 
mechanisms conferring this increased risk are unknown. Many single nucleotide 
polymorphisms have been shown to be associated with increased risk for CaP, 
although these are not necessarily causative. Some occur with higher frequency in 
populations of African descent. There is also some evidence that differences in 
androgen metabolism might account for the discrepant risk. Various oncogenic 
events, such as TMPRSS2:ERG gene fusions, also occur more commonly in men with 
African ancestry (21). Men with African ancestry have been shown to have higher 
baseline PSA values at presentation, tumours that are more locally advanced and 
with higher histological grade, shorter times to biochemical recurrence following 
treatment, and a higher overall mortality rate (12). 
  Data on cancer incidence and mortality in Africa are poor. There are very few 
population based cancer registries in Africa. The data that are available are thought 
to underestimate the true prevalence of cancers generally, but of prostate cancer in 
particular (17,22). Prostate cancer is common in South Africa, but information on 
the true incidence and mortality rate are also limited and conflicting. Some studies 
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based on histological diagnosis report a lower incidence of CaP in South Africa than 
in Western countries and a lower rate yet in black South Africans (2,23). Other 
South African studies suggest that black South Africans might share some of the 
increased risk noted in other African populations (7,24). 
Objectives 
 To form a broad overview of the worldwide epidemiology of prostate cancer. 
 To perform a more extensive review of epidemiology, clinical features, and 
treatment outcomes with respect to race, with particular focus on African 
origins. 
 To review the work done on potential underlying causes for racial disparities. 
 To review the data on prostate cancer epidemiology in sub-Saharan Africa. 
 To review the literature on prostate cancer in South Africa.  
Methodology 
A Medline search was conducted using the following MeSH terms: 
 Prostatic neoplasms / ethnology 
 Prostatic neoplasms / epidemiology, ethnology, aetiology AND Africa south of 
the Sahara 
 Prostatic neoplasms AND South Africa 
The relevance of articles was screened on title, then abstract, then body as 
necessary. Newer articles were favoured, with search limited to English language 
articles. A search on Google Scholar was also performed with search terms similar 
to those used above. Relevant references from other articles followed up as 
necessary. Other internet searches were performed as necessary for information 
such as census data and reported national cancer statistics. 
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Summary of the literature 
Global epidemiology of prostate cancer  
  Prostate cancer (CaP) is the commonest cancer that occurs in men. Autopsy 
studies have shown that the prevalence of incidental CaP is high among middle-
aged and elderly men, being proportionate to the age of the population studied. 
The exact prevalence rates vary widely between studies, based on the populations 
studied and histological techniques used. In a meta-analysis of the literature on this 
topic, Rebbeck and Haas (25) concluded that more than a third of men over 60 
years of age had latent prostate cancer.   
 
  The most comprehensive report of worldwide cancer incidence and mortality is 
the GLOBOCAN series, which is an ongoing project run by the International Agency 
for Research on Cancer, a division of the World Health Organisation (11). This 
project uses available cancer statistics from around the world, as well as inferred 
data from countries where such information is not readily available. They estimate 
that in 2012 there were 1.1 million new cases of CaP and that there were over three 
hundred thousand deaths attributable to CaP. Worldwide, the average man has a 
cumulative lifelong risk of 3.8% of being diagnosed with prostate cancer, which is 
second only to lung cancer (at 3.9%). In developed countries, CaP is the most 
common cancer diagnosed in men. This is thought to be due to the more 
widespread use of PSA screening in those countries. Developed countries accounted 
for 70% of the CaP diagnoses worldwide in 2012. 
  The population of Africa comprises approximately 15.5% of the world population 
(26) but GLOBOCAN estimates the cancer incidence in Africa at 6.0% and mortality 
at 7.2%. Although Africa has the youngest population of any continent (26), the 
figures might still suggest that the cancer burden in Africa is somewhat 
underestimated. Crocker-Buque, et al (17) concluded that the cancer registration 
systems used to calculate incidences in sub-Saharan Africa for the GLOBOCAN 2008 
report were of poor quality, with 20 African countries having no registration 
systems at all. There is a large variation in mortality and incidence rates of CaP 
between regions, with mortality rates varying 10-fold and incidence rates varying 
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24-fold (1). The regions with the highest incidence in the world are Australia/New 
Zealand, North America, and Scandinavia, among others. The highest mortality rates 
are noted in the Caribbean as well as isolated countries in South America and sub-
Saharan Africa. 
Secular trends in Prostate Cancer Incidence 
  Beginning in the late 1980’s and into the 1990’s, there was a dramatic increase in 
the incidence of prostate cancer in the United States. This was initially due to more 
transurethral resection of the prostate being performed, and later due to the rising 
use of PSA screening on the asymptomatic male population (27). This has led to a 
stage migration in prostate cancer, with a much greater proportion of men now 
being diagnosed with localised disease. 
  During the same period, prostate cancer survival has increased dramatically. This is 
due to both a lead time bias and also to the “Will Rogers effect” of including men 
with clinically insignificant disease who would previously not have been recognised 
as having prostate cancer (28). 
  People over the age of 60 years comprise the fastest growing segment of the 
worldwide population, growing at 3.26% year on year (26). Largely because of the 
ageing population, the worldwide incidence of prostate cancer is predicted to rise 
to 1.7 million cases and 499 000 deaths by the year 2030 (1). 
 
Prostate cancer in people of African descent 
  The transatlantic slave trade transported approximately 15 million people from 
West Africa to Europe, the Americas and the Caribbean during the 15th to 19th 
centuries (29). That number does not include the many millions who died en route. 
The areas from which these people were taken are primarily in the present day 
countries of Benin, Nigeria, Ghana, Gambia, Senegal, Mozambique, and Angola. This 
accounts for the majority of African ancestry in those countries that were supplied 
with slaves during that time. 
  African ancestry, particularly West African ancestry, is a very well-established risk 
factor for CaP (30). Although the direct cause of prostate cancer remains elusive, 
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there is clearly a heritable component to the disease. This is demonstrated by the 
correlation between family history and personal risk of CaP diagnosis (3). 
Incidence 
  Rates of prostate cancer in populations of African descent are the highest in the 
world (31). The age-standardised rate (ASR) of CaP incidence in African American 
men (AAM) between 1999 and 2008 was 239 cases per 100,000 compared to a rate 
of 151 in European American men (EAM), indicating a relative risk for diagnosis of 
1.59 (18). The age adjusted incidence of prostate cancer in men from Kingston, 
Jamaica in the early 1990’s was calculated as 304 per 100,000 (14). A more recent 
study from Barbados calculated the incidence at 160 per 100,000 (32). Although this 
rate was lower than the incidence noted in African American men, the mortality 
rate for CaP that the authors calculated was higher in the Barbados community than 
that reported for the African American population. Incidences rates have also been 
shown to be higher in Brazilian men of African descent compared to their white 
countrymen, with risk 1.59 fold higher (15). The Prostate Conditions in Ethnic 
Subgroups Study (PROCESS) was a UK-based retrospective cohort study that 
examined the incidence and clinical features in men that had been diagnosed with 
CaP within a set geographical area. The study was designed to compare black men 
with their white counterparts living in those specific areas. The main finding of the 
study was that the incidence of CaP in black men was three times that of the white 
men (166/100,000 vs 56.4/100,000). The increased risk was more pronounced in 
the younger age groups (13). 
Prevalence  
  Autopsy studies have shown that undiagnosed or latent CaP is much more 
prevalent in men of African descent. Rebbeck and Haas (25) performed a 
comprehensive review of autopsy studies on the subject. They identified 58 studies 
that looked for latent prostate cancer in men who had died of unrelated causes. 
They found that prevalence across all race groups increased progressively with age. 
Men of African descent reached 50% prevalence by the age of 60 years, whereas 
men of European and Asian descent reached 50% prevalence at age 80 and 90 
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years, respectively. Latent prostate cancer under the age of 40 was found in 37% of 
African men, 9% of European men, and 4% of Asian men.  
Grade, Stage and Positive Surgical Margins 
  Other clinical characteristics have also been shown to be worse in black men. It is 
postulated that men with African ancestry are prone to prostate cancer that is more 
aggressive and that progresses more rapidly than in their contemporaries (33). 
  A large autopsy series from Detroit (4) that included men who had died of causes 
other than prostate cancer showed that AA and EA men had similar prevalence 
rates of HG PIN and latent CaP when younger than 60 years. It seemed that 
transformation to significant disease occurred at an earlier age in AA men. 
  When on active surveillance (AS), black patients have been shown to be more 
likely to be histologically upgraded on repeat biopsy. In one study of men fulfilling 
the NCCN very low risk criteria who were on active surveillance, 36% of AA patients 
were upgraded on serial biopsy compared to 16% of EA patients (34). 
  An analysis of all of the radical prostatectomies done at Johns Hopkins between 
1992 and 2013 was performed by Faisal, et al (35). It was found that low-risk African 
American men were significantly more likely to have had upgrading, upstaging and 
positive margins.  
  Another study from Johns Hopkins analysed RP specimens of patients who had had 
NCCN very low risk disease preoperatively, selecting 89 EAM and 87 AAM that had 
been treated between 2004 and 2012 (36). Compared to EAM, AAM were 
significantly more likely to have extraprostatic disease (14.9% vs 3.4%), positive 
surgical margins (19.8% vs 5.6%) and upgrading to Gleason 7 or above (36.8% vs 
11.2%).  Total tumour volume was found to be higher in AA men (0.423 vs 0.185 
cm3) and AA men were more likely to have multifocal disease (83.9% vs 60.7%). 
When considering the size and location of dominant nodules, it was found that AA 
men were more likely to have an anteriorly situated dominant nodule (50.6% vs 
28.7%), which were more likely to be greater than 0.5 cm3 (31.0% vs 13.5%). These 
anteriorly situated tumours, especially the large ones, seemed to account for much 
of the histological upgrading in the AA men.  
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  Ha, et al analysed their series of men who had had radical prostatectomies who 
would have been candidates for active surveillance. They found that non-organ-
confined disease was present in 9.4-10.1% of white patients, whereas 15.8-19.4% of 
the AA patients were similarly upstaged (the risks varying depending on the AS 
criteria used). In this study, there was no statistically significant difference in 
upgrading of cancer (ie. higher Gleason) between African American and white 
patients (37). In a very similarly designed study, Jalloh, et al did not find significant 
differences in upstaging or upgrading, although they did find that the positive 
surgical margin rate was higher (31% vs 21%) (38). They did concede that their study 
was limited by the low proportion of AAM in the cohort (6.5%). 
  A retrospective analysis of a radical prostatectomy series by Rabbani, et al in 2009 
found that African American patients were more likely than white patients to have 
positive surgical margins (17.1% vs 11.6%). Interestingly, ethnicity was only a 
significant predictor of positive margins at the apex, with an odds ratio of 1.76 (39). 
  One potential explanation for the increased positive apical margins in black 
patients might be pelvic anatomy. Patients who have deep and narrow pelves and 
with deeply situated prostatic apices have been shown to have higher rates of 
positive margins at the apex (40). Von Bodman, et al analysed the preoperative 
MRI’s of 482 Caucasian and 103 African American patients and found that the AA 
men had steeper symphysis-pubic angles, smaller pelvic inlets and more inferiorly 
situated prostatic apices (41). They found that the depth of the prostatic apex in 
their series was independently predictive of positive apical margins, which was 
more pronounced in AA men.     
Equal Access vs Fee Paying Sysytems 
  Studies performed in so-called “equal access” healthcare systems often find fewer 
differences in the clinical and pathological features of prostate cancer. These 
systems include free national healthcare systems and the Veterans Administration 
hospitals in the US.  
  In the UK, healthcare is free at the point of delivery to all residents. An analysis of 
the PROCESS cohort determined that although the black patients were diagnosed at 
a younger age and with higher age-adjusted PSA levels, there were no differences 
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detected in prostate cancer disease characteristics such as D’Amico risk group, 
Gleason grade and pathological stage (42). 
  There have been some attempts at identifying and quantifying contributing factors 
to racial disparities in prostate cancer. Jones, et al (43) performed a multivariate 
logistic regression analysis of a pre-PSA cohort of patients to quantify the effects of 
various potential explanatory factors on stage at diagnosis and on survival. They 
calculated that modifiable factors such as sociodemographic ones and screening 
practices accounted for more than 60% of the racial difference in stage at 
presentation. AA patients were 53% more likely to die of prostate cancer during 
follow up. Histological grade of cancer accounted for just over half of the increased 
risk of death. The remainder of the increased risk was explained fully by 
socioeconomic status and medical insurance coverage.   
  The impact of insurance coverage was investigated by Fedewa, et al (44). They 
examined all of the CaP cases listed in the US National Cancer Database during 
2004-2006. They found that patients who were uninsured or on Medicaid were 
more than four times more likely to be diagnosed with CaP, compared to those with 
private health insurance. Comparing AAM with EAM in the cohort, AAM were 2.7x 
more likely to be diagnosed with CaP. Thus, insurance status seemed to account for 
a substantial portion of risk of CaP. It was also found that lack of insurance or 
Medicaid insurance and African American race were both independent predictors of 
higher PSA at diagnosis, higher clinical stage, and higher Gleason sum.  
  African ancestry has been shown to be a risk factor for a worse response to 
treatment, with lower biochemical progression-free survival and cancer-specific 
survival. 
Response to Treatment 
  The study by Faisal, et al analysing the radical prostatectomy outcomes from Johns 
Hopkins from 1992 to 2013 found that biochemical recurrence, stratified by NCCN 
risk category, was significantly worse for African American men (35). 
  Gooden, et al (45) studied the influence of surgeon and hospital volume on racial 
differences in BRFS between black and white patients. This was done by reviewing 
the SEER data for patients who had had radical prostatectomies from 1991 to 1999. 
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High volume centres and high volume surgeons produced better biochemical 
recurrence free survival rates for their patients. AAM were more likely to be 
operated on by a low volume surgeon, even when at a high volume centre. AAM 
were more likely to experience BCR overall, which was significant in medium and 
high volume hospitals (HR 1.30 and 1.36, respectively) even when controlling for 
multiple covariates, such as NCCN risk and surgeon volume.   
  Even in equal access healthcare systems, black patients might still have lower long 
term biochemical recurrence free survival (BRFS) rates. Schreiber, et al studied the 
outcomes following RP at New York Harbor VA, an institution serving a 
predominantly AA population (46). They found that 5 year biochemical control was 
90.2% in the EA patients but only 75.4% in the AA patients. The difference was more 
pronounced in the low risk group where 5 year BRFS was 97.6% vs 81.7%.   
Mortality 
  Population based mortality rates from prostate cancer have also been found to be 
higher among men of African descent. Often the racial disparity in mortality is less 
than that found in incidence rates due to the detection bias being less.  
  Mortality rates in African Americans have been found to be 2.4 times higher than 
in white Americans (47). This finding was based on analysis of the SEER database. It 
is not entirely clear whether the increased mortality in these populations is entirely 
due to increased prevalence of prostate cancer, or if the prostate cancer that these 
men get is also more likely to result in death.  
  The PROCESS study, mentioned above, did not find differences in mortality within 
their cohort. 
  Powell, et al (48) analysed the SEER database, looking at prostate cancer 
survivorship in the US. They compared mortality rates between AA and EA men 
during 1973-1994 to represent the pre-PSA era, and during 1998-2005 to represent 
the current PSA era. In the pre-PSA era, the overall survival was significantly lower 
(P <0.0001) for AA men, with relative survival approximately 10% lower throughout 
the period. In the PSA era more data was available on cancer stage and treatment. 
The investigators found that AA men have a higher incidence of prostate cancer, are 
more likely to present with metastatic disease, and they die on average 5 years 
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younger than their EA counterparts. However, when matched for stage at 
presentation, there was no statistically significant difference between the two 
groups. 
  Graham-Steed, et al attempted to investigate the relationship between race and 
prostate cancer specific mortality rates, controlling for healthcare access disparities 
(49). They performed a literature search for studies on race and prostate cancer 
mortality from the UK, Canada, or VA hospitals in the US. In addition, they analysed 
their own cohort of VA patients from the New England area. The five studies that 
they identified in their literature review all concluded that in those settings, overall 
and disease specific mortality rates were similar between black and white patients. 
The analysis of their cohort revealed that the black patients presented at a younger 
age, with higher PSA values, higher histological grade tumours and higher clinical 
stage compared to the white patients. Despite this, the prostate cancer specific 
mortality was not significantly different between the two groups. 
  The impact of access to healthcare on CaP mortality was also demonstrated by a 
study by Freeman, et al (50). In a sample of 833 CaP patients from the Chicago area 
during 1986-1990, socioeconomic status (SES) was estimated from the area that the 
patients lived in, and was compared to overall mortality. Patients in the lower SES 
quartile were 2.37x more likely to die of CaP than those in the highest quartile. 
Hazard ratios for death from CaP among AAM compared to EAM were 1.31 and 0.96 
in privately insured and VA patients, respectively. Also, on adjusting for SES, there 
were no statistically significant differences in mortality rates between black and 
white patients. These findings suggest that access to healthcare, socio-economic 
status, but not race, accounted for the disparities in mortality seen within the 
population. 
Biological explanations for disparities 
  Although health-seeking behaviour, access to adequate healthcare and other 
socio-economic factors account for a good deal of the racial differences in prostate 
cancer incidence, there is clearly also a biological component that contributes to 
these differences. 
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  Genome-wide association studies have revealed a number of single nucleotide 
polymorphisms (SNPs) that are associated with prostate cancer risk. This includes 
CYP3A4, 8q24, and EphB2, among many others (21). Frequencies of these alleles 
vary between AAM and EAM. 
  Differences in androgen-mediated mechanisms could also be responsible for CaP 
disparities. The CYP3A4*1B allele, which is more prevalent in AA people, results in 
less efficient oxidative deactivation of testosterone. Prostatic androgen 
concentrations have also been shown to be higher in AAM. Polymorphisms in the 
number of CAG repeats in the AR gene have been shown to affect the function of 
the androgen receptor. Long CAG repeats inhibit the receptor leading to reduced 
androgen activity. AAM have been shown to have a higher prevalence of short CAG 
repeats. Short CAG repeat length has been shown to be a risk factor for higher stage 
at diagnosis, metastasis and death from CaP (21).  
  TMPRSS2:ETS fusions are oncogenic events that were shown to be more common 
in CaP tissue from AAM, although more recent studies have actually reported a 
lower incidence (21). 
  Diabetes mellitus (DM), specifically type II DM, has been shown to be associated 
with an increased risk high grade CaP (51). The risk is higher in obese diabetics. The 
mechanisms accounting for this increased risk are unknown. The Centers for 
Disease Control and Prevention (CDC) estimate that the prevalence of DM in African 
Americans over the age of 20 is 18.7%, compared to a rate of 10.2% in whites (52). 
This could partly account for the increased incidence of CaP among AA men. 
  Differences in vitamin D levels and the vitamin D receptor have also been thought 
to play a role in CaP incidence, but data on this are inconclusive (21). 
  Other environmental influences, such as level of exercise, trans fatty acid intake 
and cooking practices, have also been implicated (53–55). 
Summary 
  To summarise, it is clear that men with African ancestry have a greater risk of 
being diagnosed with prostate cancer and that that risk is higher in the younger age 
groups. This is probably due to a higher prevalence in those populations, but the 
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differences in incidence might be more pronounced because of more aggressive 
screening practices in those populations.  
  Differences in stage of presentation, pathological features, positive margins, 
biochemical recurrence and cancer specific survival for prostate vary widely 
between populations, but are probably less marked in populations served by equal 
access healthcare systems. 
 
Prostate Cancer in Africa 
  Studies on the epidemiology of CaP on the African continent are few. Analysis of 
the GLOBOCAN 2012 data reveals that CaP is the commonest cancer diagnosed in 
men in Africa (56). Interestingly, the mortality to incidence ratio for CaP in Africa 
was estimated to be 71%. By contrast, the number of deaths due to prostate cancer 
in North America in 2012 was only 13.1% of the total number of new cases (11). The 
high incidence to mortality ratio in Africa is indicative of a high level of 
underdiagnosis of CaP. 
  Zimbabwe is one of the few sub-Saharan African countries with a population based 
national cancer registry (56). Data from the city of Harare are considered the most 
reliable. The incidence of CaP in the black population of Harare has been noted to 
be increasing at a rate of 6.4% annually over the last twenty years. The ASR for CaP 
was calculated as 30.1 in 1991-1995, rising progressively to 73.3 in 2006-2010 (57). 
This is the highest ASR reported for CaP in any African population, although notably 
still around half the incidence of CaP in white Americans. In the time period 1991-
1997 the age standardised incidence of prostate cancer in Harare was 15% higher in 
whites, but by 2004-2010 it was 33% higher in the black population. This was due 
entirely to the rising incidence in black men (58). Screening for CaP is said to be 
uncommon in Zimbabwe. The authors of these studies postulate that the rising 
incidence might be due to increased awareness of CaP, more transurethral or open 
surgery being performed for LUTS, and to more histological analysis being 
performed on such operative specimens (57). 
  The incidence of CaP has also been shown to be rising rapidly in Maputo, 
Mozambique. It is now the most commonly diagnosed cancer in men, with an ASR 
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of 61.7 per 100,000. This figure was calculated from a pathology based registry held 
at the central referral hospital in the city. The authors of this study also indicate that 
the rising incidence is most likely not due to screening for prostate cancer, and 
might be due to similar reasons as those mentioned in the Harare study above (59). 
  The age standardised rate of prostate cancer in Kampala, Uganda was calculated as 
39.6 per 100,000 in the years 2002-2006. The rate in Kampala has been rising by 
approximately 4.5% annually over the last 25 years (60). 
  West Africa is the region that would be of particular interest in prostate cancer 
epidemiology. It was the centre of the transatlantic slave trade from the 15th to the 
19th centuries, and thus is the ancestral population of most of the “African 
diaspora” throughout Europe, the Caribbean and the Americas (29). Secondly, the 
Niger-Congo (or Niger-Kordofanian) group of languages originated in West Africa 
within the last 10,000 years. The Bantu language group of central, Eastern and 
Southern Africa is part of the Niger-Congo family. The Bantu expansion of people 
began from West Africa approximately 5,000 years ago, largely displacing existing 
populations as it progressed into central Africa, then eastwards and southwards. 
Genetic admixture seems to have been relatively minimal during much of this 
process, resulting in a good correlation between genetic and linguistic lineage 
(61,62). So despite the fact that within population genetic diversity is greatest in 
African populations (63), it is plausible that a genetic risk factor for prostate cancer 
might be shared by populations as widely separated as African Americans and 
Southern African Bantu speakers. Comparing the distribution of prostate cancer risk 
within Africa to the distribution of the Niger-Congo language group (see figure 1) 
and bearing in mind the abovementioned inadequacies in CaP epidemiology in 
Africa, it is also plausible that increased risk for prostate cancer might correlate 
more specifically with Niger-Congolese ancestry. 
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Figure 1A: Distribution of Niger-Congo languages – Image in the public domain, from 
https://commons.wikimedia.org/w/index.php?curid=2987335.(64). 
Figure 1B: Incidence rates of prostate cancer in Africa – Image from Parkin et al, Cancer Epidemiol Biomarkers 
Prev, 2014 (56).   
   
  The ASR in Conakry, Guinea in 1992-1995 was found to be 8.1 per 100,000 (65). 
The authors mention that screening for CaP and histological examination of 
prostatectomy specimens did not occur in the area at the time. 
  Between 1995 and 1997, the ASR for CaP in Abidjan, Ivory Coast was 31.4 per 
100,000, where it was the most commonly diagnosed cancer in men (66). 
  A study from Nigeria summarising the cancer registries of Ibadan and Abuja 
showed that prostate cancer was the most common cancer diagnosed in men in 
both areas during the period of 2009-2010 (67). The calculated ASR for CaP of both 
areas combined was 19.1 per 100,000. 
  Laryea, et al reported the results of a population based cancer registry in Kumasi, 
Ghana for 2012 (68). Although CaP was the second most commonly diagnosed 
cancer in males after liver cancer, the estimated ASR was only 1.7 per 100,000. 
  The reported low incidence of CaP in Ghana might be misleading. Hsing, et al 
performed a population based screening project in Accra, Ghana in 2004-2006 that 
involved 1037 healthy men who were randomly selected for recruitment (20). As an 
indication of the prevalence of screening within that population, only 2.4% of the 
study participants (aged 50-74) had ever had a PSA test. To contrast, it was found in 
2001 that 75% of American men over 50 years of age had had at least one prior PSA 
MJ Dewar – Investigating racial differences in clinical and pathological features of prostate cancer in South African men 
University of Cape Town May 2016 28 
test (69). What was found in Ghana was that 352 (33.9%) of the men screened had 
either an elevated PSA or an abnormal DRE. 307 patients underwent TRUS-guided 
biopsy and 73 were confirmed to have CaP. Using a cut off PSA value of 4.0 ng/ml, 
the screening detected prevalence was 5.8%. In white Americans this value is 1.6%, 
while in African Americans rates vary from 2.2% to 5.4%. This important study 
suggests that the incidence of CaP in West Africa might be similar to that of African 
Americans if screening practices were the same. It also illustrates that even with 
good population based cancer registries, comparisons between incidence rates 
might be misleading if screening practices are not taken into account. 
  A study conducted in rural Nigeria by Ukoli, et al randomly invited men for PSA 
testing (70). 15.7% of men over the age of 50 years had PSA values of ≥4.0 ng/ml. 
None of the men, however, underwent prostate biopsy. In the previously 
mentioned Ghanaian study by Hsing, et al, 16.0% of men had similarly elevated PSA 
values. This could indicate that the prevalence of latent cancer in Nigeria might be 
similar to that found in Ghana. 
  In North Africa, the rates of prostate cancer tend to be lower than in sub-Saharan 
Africa. The age standardised rates have been reported as 11.4 in Libya, 5.4 in 
Algeria, 7.9 in Tunisia, and 7.5 in Egypt (71).  
 
Prostate cancer in South Africa 
  The information on prostate cancer epidemiology is scanty in comparison to that 
of more developed countries. 
  The South African National Cancer Registry was set up in 1986. Prior to this, all 
epidemiological data on prostate cancer was derived either from death certification 
or from institutional case series (2,6,72–75).  
  South African studies tend to report race as one of four categories, mirroring the 
categorisation used in the South African Census. Those are black, white, coloured 
and Asian/Indian. The coloured race group refers to South Africans of mixed 
ancestry, and is sometimes referred to in the literature as “Cape Mixed Ancestry”. 
The major ancestral components of this population are Khoesan, Bantu-speaking 
African, European and Asian (76). 
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  Several of the reports on prostate cancer mortality from the 1960’s and 1970’s 
excluded black South Africans because it was felt that death notification in that 
segment of the population was too sporadic and thus insufficient (72,73). Bradshaw 
and Harington reported in 1982 on the deaths in South Africa due to various types 
of cancer (6). They found that between 1970 and 1974, the mortality rate from CaP 
amongst whites was 17-19 per 100,000, and for coloureds it was 13-17 per 100,000. 
These figures were both higher than those of the USA or the UK, which had been 
reported at 14 and 12, respectively.  The report also found that the mortality rate 
for prostate cancer was far lower in black and Asian men – the highest recorded 
rate for both groups was 8 per 100,000.    
 
  There is only one population based cancer registry in South Africa. It covers several 
rural areas in the former Transkei region of the Eastern Cape. The registry was set 
up by the Medical Research Council in 1981, mainly to monitor oesophageal cancer, 
which is particularly common in that area. The vast majority of the population 
covered are Xhosa-speaking black Africans. The most recent summary of that 
registry was published in 2015 (77), comparing various time periods from 1998 to 
2012.  The age standardised incidence rate for prostate cancer was found to be 4.4 
per 100,000 in 1998-2002, rising to 9.9 in 2008-2012. In comparison, the national 
ASR for CaP as reported by the NCR for the year 2000 was 33.47 (78). The national 
rate is based on a pathology based registry, which would be expected to have a 
lower pickup rate for cancers than a population based one. In their discussion, the 
authors do not offer a hypothesis to explain the unexpectedly low incidence, 
although they think that the progressively increasing incidence might be related to 
more awareness, improved healthcare delivery, and better access to TURP. 
 
  The South African Prostate Cancer Study (SAPCS) is an international project being 
run by the Garvan Institute of Medical Research in conjunction with the J. Craig 
Venter Institute and the universities of Limpopo, Pretoria and New South Wales. It 
is a population based study that is recruiting black South African men with and 
without prostate cancer from various urology services in the Gauteng and the 
Limpopo Provinces. They aim to analyse their genetic profiles and to follow them up 
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in a longitudinal manner. Their stated goal is to investigate genetic and 
environmental risk factors in an “as yet un-investigated, potentially high risk 
population” to better understand global disparities in CaP, particularly those 
pertaining to African ancestry (79). 
  A report on the clinical presentation of approximately the first 1000 participants 
was recently published (24). The majority of their patients had presented with LUTS 
and presentation for screening was uncommon.  The investigators also found that 
the men with CaP presented with more aggressive and more advanced disease. 83% 
presented with a PSA level of ≥20ng/ml, with a median PSA of 98.8ng/ml. 36% had 
Gleason score of ≥8. By contrast, the majority of men in the US are diagnosed with 
CaP after being screened, and only 16-17% are diagnosed with Gleason 8 or higher. 
  The group initially began by performing genome-wide association studies (GWAS) 
incorporating multiple single nucleotide polymorphisms (SNP) that were developed 
mostly in European populations. The findings were that these studies were not 
predictive of disease in the SAPCS population, indicating that these are probably not 
appropriate for clinical use in a Southern African Bantu population (79). The 
investigators speculate that some of the reasons for the discrepancies might be 
socioeconomic factors, late presentation and the lack of PSA screening. 
 
  Heyns, et al conducted a study in 2000-2001 screening attendees of the Urology 
clinic at Tygerberg Hospital in the Western Cape for prostate cancer using a DRE and 
PSA level. They found, in a cohort averaging 59.4 years of age, that 9.6% of the 
screened men had PSA values above 4ng/ml. Black patients were less likely to have 
high PSA levels than coloured patients, although there was no indication of whether 
this was statistically significant or not. There were 400 black patients screened, of 
whom 31 had abnormal PSA values. Only 6 of them had biopsies, two of which were 
positive for cancer.  
  In another study by Heyns and colleagues (7), an analysis was performed of all the 
patients diagnosed with prostate cancer at Tygerberg Hospital from 1995 to 2005. 
They considered the patients’ self-assigned race, their PSA value, the findings on 
DRE, the histological grade and whether the disease was localised or metastatic. 
The study included 901 patients, 32% of whom were white, 59.8% coloured and 
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7.9% black. PSA values were high. The median PSA of the group as a whole was 
33.5, with a mean of 526.3 ng/ml. Median PSA values were highest in the black 
group, being 105 ng/ml, compared to 19.6 ng/ml in the white group and 42.5 ng/ml 
in the coloured group. The white patients presented more commonly with T1-T2 
disease (53%), compared to the black and coloured patients, who presented more 
often with T3-T4 disease (62% and 61%, respectively). Black patients also had higher 
histological grade tumours on biopsy. The pathology laboratory reported according 
to the MD Anderson grading system (80) which grades CaP from 1 to 3 – low, 
intermediate and high grade. Grade 1 was the most common grade in white (37%) 
and coloured groups (39%), while black patients were most commonly diagnosed 
with grade 2 tumours (39%). Of the patients whose M-stage was known, 53% of 
black men had metastatic disease at presentation, compared to 28% of white 
patients. Although the mean age at presentation was significantly higher for the 
white patients, they were the most likely to be given potentially curative treatment. 
31% of whites, 23% of coloureds and 12% of black patients were given radical 
treatment. The vast majority of black patients (88%) were treated with initial 
androgen deprivation therapy or with watchful waiting. Outcome data was not 
available for this cohort, but mortality was tentatively inferred from the duration of 
follow-up, which was significantly shorter for the black patients (24 months) than it 
was for the white (35 months) or coloured patients (31.5 months). 
  This study is particularly pertinent to our current study, since it also covers a Cape 
Town population, with similar socio-economic status and in an overlapping time 
period. The most salient finding of this paper was that men who access the public 
health services in Cape Town are diagnosed with CaP when the disease is more 
advanced than their counterparts in the US. Furthermore, black patients in the 
Western Cape present even later than the white and coloured patients do. No 
inferences can be made as to incidence rates for the population or whether one 
group might have a higher incidence than any other.  A recent study from KwaZulu-
Natal also found that there was high proportion of men presenting with locally 
advanced and metastatic CaP (81).  
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  South Africa is one of the few African countries to have a national cancer registry. 
Ours is a pathology based registry rather than a population based one, so it does 
not include cancers diagnosed on clinical, radiological or post-mortem investigation. 
A pathology based registry also does not include clinical information such as 
presentation, tumour stage, treatment given, or outcome. The South African 
National Cancer Registry (NCR) is a program run jointly by the National Health 
Laboratory Service (NHLS) and the Medical Research Council (MRC). 
  A recent paper by Babb, et al (2) summarises the data on CaP in South Africa from 
the NCR (1986-2006), as well as mortality data obtained from death certificates by 
Statistics SA (1997-2009). Race categories used for the NCR are the same as those 
used in the national census, being: black, white, coloured (mixed ancestry), and 
Asian/Indian. Racial categories for cause of death were only available for 2009. 
  The authors report a steady increase in the incidence of CaP over the 20 years 
from 1986 to 2006, with the most rapid increase being between the years 1996 and 
1999. Since 1996, CaP has been the most commonly diagnosed cancer in men in 
South Africa. The mean age of diagnosis in 2006 was 68 years, which was not 
significantly different between race groups. Diagnosis of CaP was shown to be very 
rare below 45 years, with a steady increase with age to a peak at 75 to 80 yrs. The 
ASR for CaP in 1986 was 17 per 100,000, increasing to 27 per 100,000 on 2006. In 
2006 the ASR amongst black men was 12 per 100,000 compared to their white 
contemporaries at 52 per 100,000. In fact, every year since 1986 without exception, 
there were more individual cases of CaP diagnosed in white patients than in black 
patients – despite the fact that whites are a minority group in the population.  
  The mortality from CaP in South Africa is also increasing steadily. CaP is now the 
second leading cause of death due to cancer among men, accounting for 13% of 
cancer deaths. Lung cancer is the commonest at 19%. The age standardised 
mortality rate for CaP rose from 12.29 per 100,000 in 1997 to 16.67 per 100,000 in 
2009. Only 11% of the men who died from CaP in 2009 were white, while 42% were 
black, 22% coloured, 2% Asian/Indian, and 23% from an unknown population group. 
  The authors of this study concede that the incidence and mortality rates are 
almost certainly underestimated across the board, but especially in the black 
population. They suggest a number of reasons for this. Firstly, since the NCR is a 
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pathology based registry, the cases that have been diagnosed on clinical grounds 
(ie. PSA, DRE, radiology) would not be included in the registry. Secondly, black men 
might be underdiagnosed more because of reduced access to medical care, or 
reduced use of these facilities. In the public sector, PSA screening is generally not 
available, while in the private sector it might be more commonly practiced. The 
authors point out that almost 70% of white people in South Africa have private 
medical insurance, while only 8.9% of the black population do. This suggests that in 
South Africa, white men are much more likely than black men to be screened for 
CaP. Because of competing mortality and a lower life-expectancy in the black 
population, black men in this country are less likely to live long enough to be 
diagnosed with CaP. The lower incidence might thus be partly due to the younger 
mean age of the black population.  
  One notable finding from this study that was not dealt with in the discussion was 
the very high age adjusted mortality rate for the coloured population.  The rate per 
100,000 for black men was 11.4, for white men was 6.8, for Asian/Indian men was 
6.3, but for coloured men it was 51.9. The highest reported national rate in the 
world is 53.6 per 100,000 in Trinidad and Tobago, which is more than double the 
second highest mortality rate of 22.6 in Cuba (1). The reason for the very high 
mortality rate in the coloured population was not speculated upon. 
Further research 
  This literature review has identified several deficiencies in the knowledge base of 
the epidemiology of prostate cancer. 
  The causes of the increased risk for CaP faced by men with African ancestry are 
poorly understood. Also, it is not certain whether established genetic risk factors 
are applicable to South African populations. Genetic based studies such as the 
South African Prostate Cancer Study and the Johannesburg Cancer Case Control 
Study will hopefully shed light on these genetic associations and perhaps on the 
underlying aetiology of prostate cancer. 
  Although it has been clearly established that CaP is more common and occurs at a 
younger age in men of African descent, the statistics that are available for 
populations in Africa are generally of very poor quality or non-existent. The 
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establishment of population based cancer registries in Africa would greatly improve 
knowledge in this area. 
  In South Africa in particular, a national population based cancer registry would give 
much better estimates of our cancer incidences and outcomes. Because of our 
better infrastructure and healthcare system, this is a lot more feasible than 
establishing and maintaining such registries elsewhere in Africa. 
  The finding by Babb, et al (2) that the prostate cancer mortality among coloured 
men in South Africa in 2009 was calculated as 51.9 needs to be verified and, if it is 
that high, then the underlying reasons should be sought out. 
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Abstract 
Background:  Men with African ancestry living in Europe and the Americas are at 
higher risk of being diagnosed with prostate cancer, are diagnosed at a younger age, 
and might have more severe disease characteristics. Published reports present a 
conflicting picture of the disease South Africa, and it is unclear whether black South 
African men share this increased risk. 
Objectives: We aimed to study the clinical and pathological features of men 
undergoing prostate biopsy from different racial backgrounds in South Africa, in an 
attempt to characterise the disease locally. Our hypothesis was that black African 
men presenting to our service had more severe disease characteristics than other 
patients.  
Materials and methods: All patients who underwent a prostate biopsy at Groote 
Schuur Hospital, Cape Town from July 2008 to July 2014 were studied. For each 
patient, data were collected on age, self-assigned race, presenting symptoms, 
prostate-specific antigen (PSA) level, prostate volume, and histological diagnosis.  
Results: A total of 1016 patients were studied. 162 (15.9%) were black and 854 
(84.1%) were coloured (mixed ancestry), white, or Asian. Black patients were 
compared as a group to the coloured, white and Asian patients. The black patients 
in the series had higher PSA values (mean 167.8 vs 47.7, median 16.4 vs 10.9, p < 
0.001). They were more likely to be diagnosed with cancer (57.4% vs 44.5%, p = 
0.003), to present with locally advanced cancer (T3/4 16.1% vs 8.9%, p = 0.028), and 
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to have high grade disease (Gleason ≥ 8 45.2% vs 30.5%, p = 0.011). There was no 
difference in age, presenting symptoms, or prostate volume.  
Conclusion: The black men diagnosed with prostate cancer at Groote Schuur 
Hospital had significantly worse clinical and pathological characteristics than the 
non-black men. Interpreting these differences as representative of a more common 
or aggressive disease among black men is not possible due to study limitations.      
Introduction  
  Cancer of the prostate (CaP) is one of the most common cancers diagnosed in 
men. Worldwide, it is the second most common non-cutaneous cancer in men and 
it is the fifth commonest cause of death due to cancer (11). In South Africa, prostate 
cancer is the most frequently diagnosed cancer in men, and second only to lung 
cancer in terms of mortality (2). 
  African American men have been shown to have a higher incidence of prostate 
cancer, higher stage at presentation, higher histological grade, a greater propensity 
to relapse after curative treatment, and a higher disease-specific mortality (3,4). 
Men with West-African ancestry living elsewhere, such as South America, the 
United Kingdom and the Caribbean, have similarly high rates of prostate cancer 
(5,14,15). Delayed diagnosis accounts in part for the higher stage at presentation 
and possibly some of the increased mortality. This delay in diagnosis has been 
attributed to healthcare access problems, reduced health-seeking behaviour, and 
often health-provider prejudice (82). Once diagnosed with prostate cancer, lower 
socio-economic status can, in many instances, lead to inferior management and 
worse outcomes following treatment. Studies attempting to correct for these 
factors conclude that they do not account all of the discrepancies seen and that 
some of the differences in disease characteristics must be due to differences in 
tumour biology between African American men and other American men (83). 
These are most likely the result of underlying genetic factors (4).  The exact 
mechanisms conferring this increased risk are unknown. Many single nucleotide 
polymorphisms have been shown to be associated with increased risk for CaP, 
although these are not necessarily causative. Some occur with higher frequency in 
populations of African descent. There is also some evidence that differences in 
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androgen metabolism might account for the discrepant risk. Various oncogenic 
events contributing to the pathogenesis of CaP, such as TMPRSS2:ERG gene fusions, 
also occur more commonly in men with African ancestry (21). 
  Epidemiological studies on populations within Africa report far lower incidences of 
prostate cancer than those reported in populations of African descent in Europe 
and the Americas (56). There is some evidence, however, that these rates are 
misleadingly low due to underdiagnosis and underreporting of cases (20,70). 
 Heyns, et al analysed the series of patients that were diagnosed with CaP at 
Tygerberg Hospital in Cape Town between 1995 and 2005. Compared to their white 
and coloured (or mixed ancestry) contemporaries, the black patients had higher PSA 
values at presentation, more locally advanced and higher grade tumours (7). The 
impression of those authors was that prostate cancer was more common in black 
South Africans than in other population groups, possibly in a similar way to African 
American populations. However, epidemiological studies on South African 
populations have uniformly found prostate cancer to be more common in white 
than black South Africans (2,6). These seemingly discordant findings suggest that 
prostate cancer in the South African black population might be underdiagnosed to a 
large extent. Prostate cancer incidence within a population is heavily influenced by 
screening practices. Due to lower socio-economic status, the average black male in 
South Africa might be less likely to be screened for prostate cancer, and thus be less 
likely to have a prostate biopsy than one of his white, coloured or Asian 
counterparts. This is illustrated by the finding that the biopsy-proven incidence in 
black men in South Africa is less than a quarter that of white South African men, but 
their mortality rate is more than double (2).     
  It has also been our overall impression that of the men being referred for prostate 
biopsy in our unit, the black patients seemed to have higher PSA values, larger 
prostates, be more symptomatic, and have a higher chance of having prostate 
cancer diagnosed.  We therefore set out to analyse our biopsy database to 
determine if that is the case. 
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Materials and Methods 
  Approval for the study was obtained by the human research ethics committee of 
the University of Cape Town. A comprehensive literature review on the topic of 
prostate cancer and race was carried out using Medline and Google Scholar.  
  The study was performed within the Division of Urology at Groote Schuur Hospital 
in Cape Town, South Africa. Since 2008, the division has prospectively kept a 
database of all the patients undergoing prostate biopsy. Data collected include 
demographic information, PSA value, presenting symptoms, findings on digital 
rectal examination (DRE), and histopathology results. All patients had been referred 
to the urology service via normal channels and had biopsies as part of routine 
clinical care. Indications for prostate biopsy included an elevated serum PSA level or 
an abnormal DRE. We routinely perform a 12 core transrectal ultrasound-guided 
biopsy under local anaesthetic. Any abnormal areas noted on TRUS are biopsied 
with additional cores.  
  A retrospective analysis of the database was performed, covering the patients 
biopsied between July 2008 and June 2014. Patients’ self-assigned race, as recorded 
by hospital administration staff, was obtained from the electronic patient record 
database. Patients were excluded if PSA value, histology result or self-assigned race 
was not available.  The data was analysed with the assistance of a statistician, with 
special emphasis on clinical and pathological characteristics correlated with race 
group.  
  The 2011 South African Census reported that the demographic profile of the city of 
Cape Town was 38.6% black African, 42.4% coloured (mixed race), 15.7% white, 
1.4% Asian, and 1.9% other (84). The population breakdown of people over the age 
of 65 was 14.4% black, 39.0% coloured, 43.3% white, 1.5% Asian, and 1.9% other – 
the differences possibly due to different patterns of migration and discrepant life 
expectancy. The hospital record-keeping system uses the same race categories as 
those used in the census. The coloured population of South Africa is largely based in 
the Western Cape Province, which makes the proportion of coloured people living 
in Cape Town much higher than the national average, while the black population 
comprises a corresponding lower proportion of the total population. The 
MJ Dewar – Investigating racial differences in clinical and pathological features of prostate cancer in South African men 
University of Cape Town May 2016 45 
percentage of people of Indian descent living in the Western Cape is lower than in 
KwaZulu-Natal or Gauteng. 
  Our working hypothesis was that the black patients within our population might 
present with higher serum PSA levels, larger prostates, more locally advanced 
tumours, and tumours of a higher histological grade. We also thought that black 
patients might be more likely to present with lower urinary tract symptoms, and 
less likely to have been biopsied as a result of PSA screening. In keeping with our 
hypothesis that black patients might have worse clinical and pathological features, 
we compared the coloured, white and Asian patients as a group (“non-black” 
patients) with the black patients. Categorical data was compared using Pearson’s 
Chi-squared test. Parametric (patient age) and non-parametric (prostate volume 
measurements and PSA values) numerical data were compared using the Welch two 
sample t-test and the Wilcoxon rank sum tests, respectively. Statistical significance 
was defined as a p-value ≤ 0.05. 
Results 
  The database contained details on 1027 men. 11 patients were excluded from the 
analysis due to missing data on PSA value, race group, or histology results. Thus, a 
total of 1016 patients were included in the analysis. 162 (25.9%) were black, 757 
(74.5%) were coloured, 89 (8.8%) were white, and 8 (0.8%) were Asian. The mean 
age of the cohort was 65.8 years, and was matched across race groups (p = 0.378). 
  We examined the mode of presentation of the patients and classified them into 
four groups. Asymptomatic patients were those who presented requesting PSA 
screening without symptoms of prostate pathology, or those who were referred to 
us having had a screening PSA. Men presenting with symptoms were classified as 
having LUTS (obstructive or irritative lower urinary tract symptoms), symptoms of 
metastases (bone pain, loss of weight, paraplegia), or other (haematuria, 
haematospermia, etc). The rate of screening in this cohort was low, with only 21.5% 
of the patients being asymptomatic. The likelihood of a positive biopsy among the 
asymptomatic men was similar between the black and non-black patients (41.4% vs 
42.8%, respectively). 77.2% presented with LUTS, 0.8% with symptoms of 
metastases, and 0.7% with other symptoms. There were no statistically significant 
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differences between the race groups in terms of presenting symptoms (p = 0.731). 
More black patients presented with obstructive urinary symptoms (70.6% vs 
64.3%), but this difference did not achieve statistical significance (p=0.127). 
  Black patients presented with significantly higher PSA values than the coloured, 
white and Asian patients (p < 0.001). The mean PSA value among black patients was 
167.8 ng/ml, compared to 47.7 ng/ml in the non-black patients. The mean values in 
both groups were somewhat skewed by a few very high outliers. Median PSA values 
were 16.4 and 10.9 ng/ml, respectively (See figure 1). 
 
 
Figure 1: Scatter plot of all PSA values – black vs non-black (p < 0.001) 
 
  Mean estimated prostate volume was higher in the black patients (57.8g vs 50.6g), 
but this was not statistically significant (p = 0.165). There was also no statistically 
significant difference, with respect to race, in the PSA densities of the patients who 
had negative biopsies (mean PSA-d 0.433 ng/ml/ml in black patients vs 0.376 
ng/ml/ml in non-black patients, p=0.3603).  
  The overall positive biopsy rate was 46.6% (473/1016). Coloured, white and Asian 
patients had cancer diagnosed 44.5% (380/854) of the time, while black patients 
had positive biopsies in 57.4% (93/162). This translated into black patients having a 
29% higher chance of being diagnosed with cancer, which was highly statistically 
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significant (p = 0.003). The mean ages of men with positive biopsies were similar 
between black and non-black patients (68.3 vs 67.2 years). 
  Higher grade tumours were noted in the black patients. They were significantly 
more likely to have tumours that were Gleason ≥7 (74.4% vs 62.5%, p=0.033) and 
Gleason ≥8 (51.1% vs 36.5%, p=0.011) (see figure 2). 
 
Figure 2: Histological diagnosis – black vs non-black  
 
  Black patients were more likely to have extraprostatic disease clinically. Of the 
black patients diagnosed with cancer, 15/93 (16.1%) had T3 or T4 disease on DRE, 
compared to 34/380 (8.9%) of non-black patients (p = 0.028) (see figure 3).  
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Figure 3: DRE findings 
 
 Black Patients 
n = 162 (15.9%) 
“Non-Black” 
Patients 
n = 854 (84.1%) 
Total 
N = 1016 
p-value 
Asymptomatic 
 
29/162 (18.5%) 177/854 (21.8%) 206/1016 (21.2%) 0.731 
Obstructive 
symptoms 
115/162 (71.0%) 555/854 (65.0%) 670/1016 (66.0%) 0.125 
PSA value in ng/ml 
(mean / median)  
166.8 / 16.4  47.5 / 10.9  66.6 / 12.0 <0.001 
Prostate volume 
(mean / median) 
57.8g / 40.5g 50.6g / 40.9g 51.7g / 41.0g 0.165 
Positive biopsy 
 
93 (57.4%) 380 (44.5%) 473 (46.6%) 0.003 
Gleason ≥ 7 
 
65/93 (69.9%) 214/380 (56.3%) 307/473 (64.9%) 0.033 
Gleason ≥ 8 
 
42/93 (45.2%) 116/380 (30.5%) 158/473 (33.4%) 0.012 
DRE - T3/T4  
 
15/93 (16.1%) 34/380 (8.9%) 49/473 (10.4%) 0.028  
Table 1 – Summary of results.    
Discussion  
  Racial categorisation in medical research is a controversial area. Some authors 
contend that racial categories are arbitrary and subjective, that there is no genetic 
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basis for such classification and that they should not be used in medical research 
(85). Others have expressed concern that ongoing emphasis on race could serve to 
perpetuate racial categorisation in the literature (86). Many scientific journals 
encourage potential authors to identify the underlying causative factors, be they 
genetic or environmental, rather than report on race alone. Some feel that focus on 
race can highlight social, economic and healthcare inequalities, and act as a 
mechanism for ensuring redress (87). It has been recommended that the potential 
benefits in terms of diagnosis and research should be weighed against the potential 
social cost of doing so (88).  
  The black patients presenting to our service had more severe clinical and 
pathological features than the coloured, white and Asian patients. They presented 
with higher PSA values, had a higher risk of being diagnosed with cancer, were more 
likely to have locally advanced disease, and were more likely to have high grade 
tumours. There are several potential explanations for these observed differences. 
The equal proportions of asymptomatic black and non-black patients in the series 
suggest that the worse disease characteristics seen in our black patients was not 
due to reduced screening in that population group. Because the risk of having a 
positive biopsy was similar amongst the black and non-black men who had been 
screened, the different rate of positive biopsies was accounted for by the 
symptomatic men. It could be that black men in Cape Town only access the 
healthcare system when their symptoms are particularly severe. In a screening 
study at Tygerberg Hospital in Cape Town, Heyns et, al (89) had found it difficult to 
get prostate biopsies for the black patients with abnormal PSA values. It is therefore 
also possible that our black patients were less likely to accept the recommendation 
of prostate biopsy if they were minimally symptomatic. 
  Despite these possible explanations for the racial discrepancies seen, it seems 
likely that there is an underlying biological factor at play. The mean ages between 
race groups were matched, both overall and amongst the men diagnosed with CaP. 
This would suggest that black men were either developing prostate cancer at a 
younger age or that they were prone to more rapidly progressive disease. The 
finding that the black patients in the series were at significantly greater risk of being 
diagnosed with high grade tumours is also an indication that the cancers diagnosed 
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were more progressive and/or more longstanding. Prostate sampling bias is a 
phenomenon that arises from the random nature of the prostate biopsy – the same 
volume of cancer in a larger prostate will be more easily missed at biopsy, and 
smaller foci of higher grade tumour will similarly be missed. Because the prostate 
volumes were not significantly different between black and non-black patients, the 
differences noted were not due to such a bias. 
  When comparing our data to that of developed countries, the worse clinical and 
pathological features seen in our black patients is seemingly on a background of 
generally more severe disease among all of our patients. Overall, the patients in our 
series presented to us largely with symptomatic disease. A study published in 2001 
found that 75% of US men over the age of 50 had previously been screened for 
prostate cancer (69). The finding that only 21% of our patients were asymptomatic 
shows indirectly that the rate of PSA screening in our population is probably very 
low.   
  The overall positive biopsy rate of 46.6% is somewhat higher than those of other 
published series’ of first time TRUS-guided prostate biopsies, which one review 
reported to be 38-42% (8). Our high rate is probably another reflection of the low 
level of screening in our population.  Our patients also presented with a higher rate 
of high grade disease than that seen in other settings. Only 35.1% of our patients 
had Gleason scores of 6 or less. A review of the CaPSURE database in the US 
reported that 64.9% of men on the database had Gleason scores of 6 or less (90). 
An analysis of the Rotterdam section of the ERSPC (European Randomized Study of 
Screening for Prostate Cancer) showed that 92.5% of patients diagnosed with CaP 
via screening had a Gleason score of ≤6 (91). 
  In the same CaPSURE review mentioned above, 79.3% of the patients had PSA 
values less than 10 ng/ml, whereas only 42.8% of our patients had a PSA values less 
than 10 ng/ml.  
  Presentation with locally advanced disease (T3 or T4) was 10.4%. This rate is 
similar to that found by Hoffman, et al (11.3%) in a large retrospective series in the 
US during 1994-1995 (92). This series was accrued during the early PSA era. A US 
study analysing temporal trends in prostate cancer reported a drop in the rate of 
T3/4 tumours at diagnosis from 19.2% in 1988 to 4.4% in 1998 (93). The higher PSA 
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values, higher Gleason scores and higher rate of locally advanced tumours that we 
see in our series are indicative of delayed diagnosis. Men served by the public 
health system in South Africa are probably less likely than their European or 
American counterparts to be screened for prostate cancer when asymptomatic. It is 
also possible that when South African men do become symptomatic, they are less 
likely to be tested for prostate cancer – due to healthcare access problems, reduced 
health-seeking behaviour, or health provider practices. Black South African men 
could be more affected by these problems than coloured, white, or Asian Patients. 
  We identified several limitations to our study. It was not possible to estimate 
prostate cancer incidences, since the population we serve is poorly defined and 
there are a number of other facilities in these areas at which patients might 
undergo prostate biopsy. TRUS and biopsy were performed by multiple and 
relatively junior clinicians, possible affecting the accuracy of the prostate volume 
measurement and the targeting of the biopsy. While this factor may have reduced 
the accuracy of our results, it was spread evenly throughout the series. We also 
have no data on the incidence of biopsy-related complications, the subsequent 
management of these patients or their outcome following treatment. We only 
studied patients living in one city and accessing one hospital, so we cannot 
extrapolate those results across the entire population of South Africa. Also, our case 
series is most likely not a representative sample of the men living in Cape Town, 
since it excluded those accessing care at other public urology services and in the 
private sector. Although we found significant differences between the black and the 
non-black patients in our series, our study was not able to determine the underlying 
reasons for these discrepancies.        
 Groote Schuur is a tertiary referral hospital, with relatively few biopsies performed 
at referring hospitals. The resultant large numbers may increase the validity of the 
study.   
Conclusion 
  Our study has demonstrated that the men who had prostate biopsies at Groote 
Schuur Hospital during 2008-2014 had more severe clinical and pathological 
characteristics, compared to American and European data. 
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  The black patients we saw presented with significantly worse disease 
characteristics than their coloured, white, or Asian contemporaries. They had higher 
PSA values, were at higher risk of having cancer diagnosed, had higher grade 
tumours, and had more locally advanced disease.  
  The underlying reasons for these differences are speculative, and are likely to be 
multifactorial. Delayed presentation due to healthcare access disparities and 
different health-seeking behaviours could account for some of those differences. 
The different CaP characteristics seen could also be due to underlying biological 
factors. Whether different biological risk is due to genetic or environmental factors 
is also uncertain. Large genetic and epidemiological studies are required to answer 
these questions.   
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Part D: Appendices 
Appendix 1: Authors’ guidelines for selected journal – Urology 
Gold Journal 
This article falls into the category of Medical Oncology, for which the criteria are as 
follows: 
 Structured article 
 250 word abstract 
 Max 3000 word text 
 Max 4 figures/tables 
 Max 30 references 
The full guidelines for authors are extensive. They can be found at: 
http://www.goldjournal.net/content/authorinfo#idp1297904 
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